logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12692241 B1

PDFFull Text
Date of Patent:
Jul. 28, 2026

Filed:

Apr. 27, 2022

Substituted triazine compound

Applicant:

Nico Therapeutics, Inc., Chicago, IL (US);

Inventors:

Yusuke Inagaki, Tokyo, JP;

Yumi Yamashita, Tokyo, JP;

Hiroki Toya, Tokyo, JP;

Takuya Washio, Tokyo, JP;

Fumie Takahashi, Tokyo, JP;

Kengo Saba, Tokyo, JP;

Hiroshi Tomiyama, Nagano, JP;

Yoshinori Iwai, Nagano, JP;

Akihiko Nakamura, Nagano, JP;

Assignee:

Nico Therapeutics, Inc., Chicago, IL (US);

Attorneys:

McCarter & English, LLP

Wei Song

James M. Alburger

Primary Examiner:

Laura L Stockton

Int. Cl.
CPC ...
C07D 253/07 (2006.01); C07D 211/56 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 407/14 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01); C07F 5/02 (2006.01);
U.S. Cl.
CPC ...
C07D 253/07 (2013.01); C07D 211/56 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/14 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07F 5/027 (2013.01);
Abstract

An object of the present invention is to provide a pharmaceutical composition, particularly a compound suitable for preventing and/or treating an inflammatory disease and/or a neurodegenerative disease. The present inventors accomplished the present invention by conducting intensive studies to find a compound having an inhibitory effect on NLRP3 inflammasome activation, with the result that a substituted triazine compound is found to have the inhibitory effect on NLRP3 inflammasome activation. The substituted triazine compound of the present invention is expected to serve as a preventive and/or therapeutic drug for an inflammatory disease and/or a neurodegenerative disease.

Find Patent Forward Citations

Inagaki, Yusuke. (2026). Substituted triazine compound (U.S. Patent No. 12692241). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12692241

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…